Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides - PubMed (original) (raw)
. 1994 May 1;152(9):4310-9.
Affiliations
- PMID: 8157954
Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides
G Y Ishioka et al. J Immunol. 1994.
Abstract
Peptides that bind with high affinity to class II MHC molecules can inhibit T cell activation both in vitro and in vivo. Thus, they have been suggested as potential therapeutic agents for MHC-associated autoimmune diseases. We have constructed nonnatural peptides with high affinity for certain disease-associated MHC alleles. More specifically, a particular peptide, designated as CY-760.50, was found to have a high binding affinity for DR1, slow dissociation kinetics after binding to MHC, and prolonged stability in human serum. However, when the ability of this peptide to block peptide presentation to an influenza hemagglutinin 307-319 peptide-specific, DR1-restricted T cell clone was examined, it was found that MHC blockade could only be achieved when high concentrations of peptide were present along with Ag in the fluid phase. Thus, pretreatment of APC with MHC class II blocker, followed by removal of unbound blocker, did not result in saturation of MHC molecules, because practically immediate reacquisition of Ag-presenting capacity was observed after removal of fluid phase blocker. The pharmacokinetic behavior and the duration of blocking activity of CY-760.50 were also examined in vivo, taking advantage of the fact that the mouse MHC class II molecule I-Ab also bound CY-760.50 with high affinity. CY-760.50 administered i.v. to C57BL/6 mice was rapidly cleared from the circulation and virtually undetectable in the serum 10 min after injection. This fast clearance rate was paralleled by a similarly short duration of the MHC blockade effect. These in vivo results have implications concerning the biology of peptide-MHC interactions, and suggest that MHC blockade may not be feasible as a therapeutic approach unless effective concentrations of inhibitor can be maintained over extended periods of time in the extracellular fluids.
Similar articles
- The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo.
Lamont AG, Powell MF, Colón SM, Miles C, Grey HM, Sette A. Lamont AG, et al. J Immunol. 1990 Apr 1;144(7):2493-8. J Immunol. 1990. PMID: 2319129 - Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.
Lamont AG, Sette A, Fujinami R, Colón SM, Miles C, Grey HM. Lamont AG, et al. J Immunol. 1990 Sep 15;145(6):1687-93. J Immunol. 1990. PMID: 1697306 - Inhibition of T cell activation by blockade of MHC class II molecules.
Adorini L, Valli A, Guéry JC. Adorini L, et al. Semin Immunol. 1991 Jul;3(4):231-6. Semin Immunol. 1991. PMID: 1932705 Review. - Peptide binding by class I and class II MHC molecules.
Batalia MA, Collins EJ. Batalia MA, et al. Biopolymers. 1997;43(4):281-302. doi: 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R. Biopolymers. 1997. PMID: 9316393 Review.
Cited by
- An Insulin-Inspired Supramolecular Hydrogel for Prevention of Type 1 Diabetes.
Liu M, Wang Z, Feng D, Shang Y, Li X, Liu J, Li C, Yang Z. Liu M, et al. Adv Sci (Weinh). 2021 Apr 9;8(10):2003599. doi: 10.1002/advs.202003599. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026440 Free PMC article. - Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis.
Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, Olson GL, Forsthuber TG. Ji N, et al. J Immunol. 2013 Nov 15;191(10):5074-84. doi: 10.4049/jimmunol.1300407. Epub 2013 Oct 11. J Immunol. 2013. PMID: 24123687 Free PMC article. - Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.
Kyger M, Worley A, Huan J, McDowell H, Smith WC, Burrows GG, Mattapallil MJ, Caspi RR, Adamus G. Kyger M, et al. Transl Vis Sci Technol. 2013 Feb;2(2):1. doi: 10.1167/tvst.2.2.1. Epub 2013 Feb 5. Transl Vis Sci Technol. 2013. PMID: 24049712 Free PMC article. - Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells.
Samanta D, Mukherjee G, Ramagopal UA, Chaparro RJ, Nathenson SG, DiLorenzo TP, Almo SC. Samanta D, et al. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13682-7. doi: 10.1073/pnas.1110971108. Epub 2011 Aug 8. Proc Natl Acad Sci U S A. 2011. PMID: 21825122 Free PMC article. - Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.
Li L, Yi Z, Wang B, Tisch R. Li L, et al. J Immunol. 2009 Oct 1;183(7):4809-16. doi: 10.4049/jimmunol.0901616. Epub 2009 Sep 14. J Immunol. 2009. PMID: 19752238 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials